About Enhanc3D Genomics
Enhanc3D Genomics is a company based in Cambridge (United Kingdom) founded in 2020 by Peter Fraser, Mikhail Spivakov, and Stefan Schoenfelder. Enhanc3D Genomics has raised $11.26 million across 1 funding round from investors including Parkwalk, BGF and Bioqube Ventures. The company has 12 employees. Enhanc3D Genomics offers products and services including 3D Multi-Omics Platform and Cell Type-Specific Atlas.
- Headquarter Cambridge, United Kingdom
- Employees 12
- Founders Peter Fraser, Mikhail Spivakov, Stefan Schoenfelder
- SectorsHealthcare
- Website enhanc3dgenomics.com
- Social LinkedIn
- Legal Name Enhanc3d Genomics Ltd
- Total Equity Funding$11.26M (USD)
in 1 rounds
- Latest Funding Round$11.26M (USD), Series A
Oct 2022
- InvestorsParkwalk
& 2 more
- Employee Count12
Products & Services of Enhanc3D Genomics
Enhanc3D Genomics offers a comprehensive portfolio of products and services, including 3D Multi-Omics Platform and Cell Type-Specific Atlas.
This platform is employed to connect genetic variants to disease-driving genes across the genome for therapeutic discovery.
An atlas is used to facilitate the unlocking of decades’ worth of genomic data from numerous subjects for drug target validation.
Funding Insights of Enhanc3D Genomics
Enhanc3D Genomics has successfully raised a total of $11.26M through 1 strategic funding round. The most recent funding activity was a Series A round of $11.26 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.26M
- Total Rounds 1
- Last Round Series A — $11.26M
- First Round $11.26M
(Oct 2022)
- Investors Count 3
All 1 funding rounds of Enhanc3D Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Enhanc3D Genomics
Enhanc3D Genomics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Parkwalk, BGF and Bioqube Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech companies are invested in by Parkwalk venture capital firm. | – | parkwalkadvisors.com | London, United Kingdom | |
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland | – | bgf.co.uk | Belfast, United Kingdom | |
Life sciences investments are managed by Bioqube Ventures in Europe and the US to advance therapeutic assets and technologies. | – | bioqubeventures.com | - |
Investor details for Enhanc3D Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Enhanc3D Genomics
7 people are tracked at Enhanc3D Genomics (5 in leadership, 2 in team); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Peter Fraser | Co-Founder | Leadership |
Mikhail Spivakov | Co-Founder | Leadership |
Stefan Schoenfelder | Co-Founder | Leadership |
Debora Lucarelli | CEO | Leadership |
Jo Yarker | Head Of Biology | Leadership |
Eshwar Meduri | Senior Data Scientist | Team |
Patrizia Messina | Laboratory Manager | Team |
Complete people profiles for Enhanc3D Genomics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Enhanc3D Genomics
2 dated milestones of Enhanc3D Genomics across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Enhanc3D Genomics is founded.
- Funding First funding round of $11.3M.
Similar companies to Enhanc3D Genomics
10 companies that operate in the same segment as Enhanc3D Genomics (Clinical Trials & Research Tech), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic services are provided by Colossal's laboratory operations. | 2021 | Austin, Texas, United States | USD 617.6 M | – | – | |
Research lab engaged in pharmacological measurements on therapeutic protein variants | 2018 | United States | USD 78.19 M | – | 22 | |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare. | 2004 | Ahmedabad, Gujarat, India | – | USD 50.52 M | 902 | |
Generic injectables for oncology and anesthesiology are manufactured. | 1989 | Hyderabad, Telangana, India | – | USD 4.22 M | 228 | |
Medical research labs are provided by GALY for scientific purposes. | 2018 | Boston, Massachusetts, United States | USD 61.59 M | – | 25 | |
Laboratory focused on biotechnology & molecule research services | 2018 | Cambridge, Massachusetts, United States | USD 32.68 M | – | – | |
Laboratory delivers discovery & research in nuclear and particle physics | 1947 | United States | – | – | 2,436 | |
Research and manufacturing of hemp products are conducted by BRC. | 2017 | Monterey, California, United States | USD 25.26 M | – | 16 | |
Novel immunotherapy therapeutic targets are discovered through laboratory research. | 2019 | Branford, Connecticut, United States | USD 92 M | – | – | |
Diagnostic products including stable isotopes are supplied by the laboratory. | 1981 | Tewksbury, Massachusetts, United States | – | – | 284 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Enhanc3D Genomics
Enhanc3D Genomics was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Enhanc3D Genomics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Debora Lucarelli is the current CEO of Enhanc3D Genomics.
Enhanc3D Genomics is a funded company, having raised a total of $11.26M across 1 funding round to date. The company's 1st funding round was a Series A of $11.26M, raised on Oct 2022.
Enhanc3D Genomics has 12 employees.
Enhanc3D Genomics was founded in 2020 as a medical research lab based in Cambridge, United Kingdom. Operations center on genome sequencing studies to advance understanding in genomics. Core activities involve analyzing genetic data for research applications, with a team led by co-founders Peter Fraser, Mikhail Spivakov, and Stefan Schoenfelder, alongside CEO Debora Lucarelli. Focus remains on scientific contributions within the biotechnology sector.
Enhanc3D Genomics offers 3D Multi-Omics Platform and Cell Type-Specific Atlas.
Enhanc3D Genomics has 3 investors. Key investors include Parkwalk, BGF, and Bioqube Ventures.
Enhanc3D Genomics operates through Enhanc3d Genomics Ltd.